Study to Investigate the Influence of Compression Treatment in Patients With Pelvic Congestion Syndrome (PCS)

Sponsor
The Whiteley Clinic (Other)
Overall Status
Recruiting
CT.gov ID
NCT05553158
Collaborator
Bauerfeind (Other)
172
1
2
24
7.2

Study Details

Study Description

Brief Summary

Pelvic vein embolization (PVE) is the current treatment procedure used to treat women with Pelvic Congestion Syndrome (PCS). This treatment is not widely available, and many women when diagnosed with PCS cannot afford treatment.

The purpose of this study is to assess whether compression therapy is an effective alternative treatment to PVE for women who are unwilling or unable to undergo treatment by PVE. Compression therapy would provide a cost-effective alternative to coil embolization.

Condition or Disease Intervention/Treatment Phase
  • Device: Compression pants
  • Device: Embolization coils
N/A

Detailed Description

Women that book a consultation and have a trans-vaginal ultrasound scan at The Whiteley Clinic which confirms a diagnosis of Pelvic Congestion Syndrome (PCS) will be informed about the opportunity to participate in this study by their consultant (provided they also fulfil the inclusion/exclusion criteria). Potential participants will be given an information sheet and time to consider the study before giving written informed consent.

These women will be given a personalised pelvic vein embolization (PVE) treatment plan. Women that opt for PVE will form the control group for this study. Women that do not wish to have PVE and opt compression therapy will form the intervention group for this study. Alternatively, women may wish to not have any treatment and will not be enrolled in the study.

Each patient will be directly involved in the study for three months (Month 1, Month 2, Month 3). A quality of life and symptom questionnaire will be completed by all patients at the start of Month 1 (baseline), at the end of Month 2 (1-month post PVE or compression therapy), and at the end of Month 3.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
172 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
There are two arms in this study: control arm and interventional arm. Participants in the control arm will have pelvic vein embolization and participants in the interventional arm will have compression therapy.There are two arms in this study: control arm and interventional arm. Participants in the control arm will have pelvic vein embolization and participants in the interventional arm will have compression therapy.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Study to Investigate the Influence of Compression Treatment in Patients With Pelvic Congestion Syndrome (PCS)
Anticipated Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Nov 1, 2024
Anticipated Study Completion Date :
Nov 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Pelvic Vein Embolization (PVE)

Patients will have their pelvic veins embolized in accordance with their personalised treatment plan, based on their trans-vaginal ultrasound scan. These patients form the control group.

Device: Embolization coils
Embolization coils are used to block the veins they are positioned in. This is a standard treatment offered to patients at The Whiteley Clinic.

Experimental: Compression Therapy

Patients will wear compression pants (with leg compression if patients also have symptomatic leg varicose veins).

Device: Compression pants
Similar to compression stockings for the legs which are designed to apply pressure to improve venous return in the legs, compression pants have been designed to apply pressure to pelvic veins to improve the symptoms of Pelvic Congestion Syndrome.

Outcome Measures

Primary Outcome Measures

  1. Mean Change from Baseline in Quality of Life and Symptoms at one month post-treatment and at two months post-treatment [Baseline (start of month 0), 1 month post-treatment (end of Month 2) and two months post-treatment (end of month 3)]

    Patients will fill out a quality of life and symptoms questionnaire at the start of the study (baseline (month 0)). Patients will then undergo treatment after one month. A quality of life and symptoms questionnaire will then be filled out again one month after treatment (end of month 2), and again a month later (end of month 3). This questionnaire uses visual analogue scales to quantify quality of life and the severity of symptoms.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No

Inclusion Criteria

  • Females aged 18 - 65 years

  • Having one or more symptoms of PCS

  • Symptoms: Aching / dragging in pelvis on sitting and/or standing, aching/tender /painful vulval varicose veins, irritable bowel, irritable bladder, deep dyspareunia, low back pain, hip pain with no or very mild changes on hip x-ray.

  • Able to understand study and give written consent.

  • Able to have trans-vaginal ultrasound scan and attend for follow-up.

Exclusion Criteria

  • Under 18 years of age or over 65 years of age

  • Currently pregnant, actively trying to get pregnant, planning pregnancy within next 12 months or within 3 months of child-birth

  • Current symptoms due to diagnosed gynaecological conditions

  • Current or previous malignancy

  • Unable or refuse to consent to trans-vaginal ultrasound scan or any other aspect of the study

  • Previous abdominal or pelvic surgery (excluding diagnostic laparoscopy)

  • Previous embolization of pelvic veins

  • Previous deep vein thrombosis, pelvic embolisation, venous intervention in abdomen or pelvis (stent, filter)

  • Any vascular malformation of the pelvis or the legs apart from that diagnosed as venous reflux disease.

  • Any medical condition likely to cause death or serious ill health within the next five years.

  • Any deep venous obstruction or reflux on duplex ultrasound.

  • Unable to wear compression garments on lower abdomen / pelvis

  • Unable to wear leg compression garments

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Whiteley Clinic Guildford United Kingdom GU2 7RF

Sponsors and Collaborators

  • The Whiteley Clinic
  • Bauerfeind

Investigators

  • Principal Investigator: Mark S Whiteley, MS FRCS(Gen) MBBS, The Whiteley Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The Whiteley Clinic
ClinicalTrials.gov Identifier:
NCT05553158
Other Study ID Numbers:
  • TWC-AC-2021-03
First Posted:
Sep 23, 2022
Last Update Posted:
Sep 23, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 23, 2022